Eukaryote

OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

Retrieved on: 
Wednesday, June 15, 2022
Health, Genetics, Research, Science, Pharmaceutical, Optical, Biotechnology, RNA, Patent, Therapy, Institute of Liver and Biliary Sciences, Neuropathic pain, Technology, Hypertrophic scar, AMD, CRISPR, Plant, Research, Cas9, Eukaryote, RNA interference, Eye, Disorder, RNA transfection, Pharmaceutical industry, Vaccine

OliX Pharmaceuticals, Inc. , a leading developer of RNAi therapeutics, today announced that the Companys subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureXs mRNA technology.

Key Points: 
  • OliX Pharmaceuticals, Inc. , a leading developer of RNAi therapeutics, today announced that the Companys subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureXs mRNA technology.
  • The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
  • Once we clinically validate the technology, we plan to expand the indications of treatments to various non-hereditary eye diseases as well.
  • OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.

Advances for India as foundational CRISPR/Cas9 gene editing patent granted

Retrieved on: 
Monday, June 13, 2022
Life, Agriculture, Gene editing, Patent, CRISPR, Policy, Environment, Workforce, ERS, Intellectual property, Technology, Trade, Health, Eukaryote, Nobel Prize, Cas9, Government, Department, Department of Biotechnology, Genomics, Potash, Fine chemical, Biotechnology

This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.

Key Points: 
  • This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.
  • ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to this foundational CRISPR/Cas9 intellectual property.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: "This is a strong statement for India.
  • Technological advances have long been a national priority, and this is globally recognized with India among the top 12 destinations for biotechnology worldwide.

Advances for India as foundational CRISPR/Cas9 gene editing patent granted

Retrieved on: 
Monday, June 13, 2022
Life, Agriculture, Gene editing, Patent, CRISPR, Policy, Environment, Workforce, ERS, Intellectual property, Technology, Trade, Health, Eukaryote, Nobel Prize, Cas9, Government, Department, Department of Biotechnology, Genomics, Potash, Fine chemical, Biotechnology

This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.

Key Points: 
  • This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.
  • ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to this foundational CRISPR/Cas9 intellectual property.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: "This is a strong statement for India.
  • Technological advances have long been a national priority, and this is globally recognized with India among the top 12 destinations for biotechnology worldwide.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022
Eukaryote, B cell, European Patent Office, Nobel Prize, EPO, Plant, VP, GMP, Enzyme, Cas9, Confusion, Multimedia, View, Synthetic biology, Biofuel, CVC, Intellectual property, Emmanuelle, Research, Patent, OD, EP400, CRISPR, Human, Opposition procedure before the European Patent Office, Technology, Genomics, University, Sale, Animal, ERS, European Patent Convention, Moore v. Regents of the University of California, CEO, Pharmaceutical industry

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022
Eukaryote, B cell, European Patent Office, Nobel Prize, EPO, Plant, VP, GMP, Enzyme, Cas9, Confusion, Synthetic biology, Biofuel, CVC, Intellectual property, Emmanuelle, Research, Patent, OD, EP400, CRISPR, Human, Opposition procedure before the European Patent Office, Technology, Genomics, University, Sale, Animal, ERS, European Patent Convention, Moore v. Regents of the University of California, CEO, Pharmaceutical industry

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Metagenomi Presents Findings on Novel Families of Ultra Small, CRISPR Enzymes at the Keystone Symposia Precision Genome Engineering Conference

Retrieved on: 
Tuesday, May 3, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Small, Escherichia coli, Smarts, Patient, Gene editing, Human, SMART, Enzyme, DNA, Conference, Cas9, Eukaryote, Organic acid, Risk, Antibiotics, Archaea, Bacteria

Metagenomi , a genetic medicines company with a versatile portfolio of next-generation gene editing tools, presented findings on the identification of novel families of compact, programmable enzymes for genome editing at the Keystone Symposia Precision Genome Engineering and Emerging Cellular Therapies Conference, on April 30.

Key Points: 
  • Metagenomi , a genetic medicines company with a versatile portfolio of next-generation gene editing tools, presented findings on the identification of novel families of compact, programmable enzymes for genome editing at the Keystone Symposia Precision Genome Engineering and Emerging Cellular Therapies Conference, on April 30.
  • The presentation described SMART (SMall ARchaeal-associaTed) systems that were mined from Metagenomis proprietary metagenomics database of novel nucleases found from natural environments.
  • They are also found naturally on humans; however, to date, no Archaea have been characterized as a human pathogen.
  • The gene editing activity of these systems was demonstrated in E. coli and reconstitution of the SMART systems in vitro displayed novel biochemical characteristics.

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

Retrieved on: 
Thursday, April 21, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Protein, Board, McGovern Institute for Brain Research, Howard Hughes Medical Institute, MIT, Berkeley, Genetics, Coronavirus Scientific Advisory Board (Turkey), Plexxikon, Genentech, Research, Genomics, Yale University, Psychiatry, Cognitive science, Elan, Doctor of Philosophy, Drug discovery, Stanford University, Lists of diseases, Patient, Harvard College, Series, Allen & Company, CSO, Genome, Harvard University, Informatics, Physics, Molecular Discovery, DMS, Bristol Myers Squibb, Biology, Eukaryote, Partnership, University, James, Senior, CRISPR, Partner (business rank), Therapy, Broad Institute, Biological engineering, Synthetic biology, Pharmaceutical industry, Fine chemical, Chemistry, Brain, Octant, Neuroscience

In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.

Key Points: 
  • In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.
  • Octant also plans to develop multiple additional therapeutic programs in small molecule chaperone therapies for rare genetic diseases.
  • Immunogenetics and immunopharmacology are among the most complex areas in biology and drug discovery, with potential to impact countless patients, continued Kosuri.
  • As Chief Scientific Officer, Rick Artis will be responsible for Octant's chemistry function and drug discovery and development programs.

Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma

Retrieved on: 
Tuesday, April 12, 2022
Disease, Drug development, Eukaryote, Therapy, Degenerative disease, DNA, GTP, GSPT1, CTX, ORR, IND, Hepatocellular carcinoma, Cancer, WSE, RNA, Ribosome, Neoplasm, Technology, Protein, SALL4, Liver cancer, GLOBE, HCC, Project, Patient, TPD, Medical imaging, Pharmaceutical industry, Bevacizumab

"The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.

Key Points: 
  • "The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.
  • Captor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023.
  • Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs.
  • Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.

DGAP-News: Heidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022

Retrieved on: 
Tuesday, April 12, 2022
Online, BCMA, Company, CD37, Eukaryote, FSE, Frankfurt Stock Exchange, Calendar, Survival, AACR, Immunogenic cell death, American Association, PSMA, Cancer, ATAC, RNA, Poster, ISIN, Amanitin, Immune system, Multiple myeloma, Association, American Association for Cancer Research, HPHA, RNA polymerase II, Annual general meeting, Control, RNA transfection, Non-Hodgkin lymphoma, Antibody, Online gambling, Paint, Vaccine, Pharmaceutical industry, Fine chemical, EU, ATACS

Ladenburg, Germany, 7 April 2022 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its proprietary Amanitin-based ATAC(R) technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Key Points: 
  • Ladenburg, Germany, 7 April 2022 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its proprietary Amanitin-based ATAC(R) technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
  • Details of the poster presentation:
    The poster shows preclinical data on the synergies of ATACs(R) together with immune checkpoint inhibitors.
  • Heidelberg Pharma works with ADCs based on its proprietary ATAC(R) technology platform using Amanitin as active ingredient.
  • The proprietary technology platform is being applied to develop the Company's own therapeutic ATACs(R) as well as in third-party collaborations.

DGAP-News: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117

Retrieved on: 
Thursday, March 10, 2022
NASDAQ, Safety, Multiple myeloma, RNA transfection, Company, Frankfurt Stock Exchange, Antibody, ISIN, Achievement, Survival, ATACS, Eukaryote, Pharmacokinetics, CD37, Cancer, Non-Hodgkin lymphoma, ATAC, Lists of diseases, HPHA, Degenerative disease, Leadership, Patient, RNA polymerase II, Technology, Therapy, CSO, Control, FSE, Lymphatic system, RNA, PSMA, BCMA, Generic drug, Fine chemical, Vaccine, Heidelberg Pharma's proprietary ATAC(R) technology, Heidelberg Pharma, Magenta Therapeutics, HEIDELBERG PHARMA'S PROPRIETARY ATAC(R) TECHNOLOGY, HEIDELBERG PHARMA, MAGENTA THERAPEUTICS

Ladenburg, Germany, 10 March 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study.

Key Points: 
  • Ladenburg, Germany, 10 March 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study.
  • The achievement of this milestone triggered a milestone payment to Heidelberg Pharma.
  • MGTA-117 is an Antibody Amanitin Conjugate based on Heidelberg Pharma's proprietary ATAC(R) technology and developed by Magenta.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.